Human kininogen D3 domain polypeptide as an anti-angiogenic and anti-tumor agent
AssigneeAttenuon, LLC
InventorsFernando Doñate, Andrew P. Mazar
Life of this patent
Estimating the term…
Abstract
Human kininogen domain 3 (HK-D3) polypeptides and biologically active variants and derivatives of HK-D3 are anti-angiogenic. These molecules are used to inhibit angiogenesis or treat a disease or condition in which angiogenesis is pathogenic. Because of their anti-angiogenic potential, these molecules compounds are useful in the treatment of cancer by inhibiting or reversing the growth of primary or metastatic tumors.
Claims17
A method for inhibiting undesired cell migration, cell invasion, cell proliferation or angiogenesis in vivo, or for inducing apoptosis in vivo, comprising administering to a subject in need thereof an effective amount of:
- (a) a polypeptide that is
- (i) a variant of native HK-D3 (SEQ ID NO:
- 1) designated HK-D3v, which has the amino acid sequence SEQ ID NO:
- 3, or
- (ii) a variant of native HK-D3 (SEQ ID NO:
- 1) that has an N-terminal addition and has the sequence SEQ ID NO:
- 2,
- wherein the polypeptide has at least 20% of the activity of native HK-D3 (SEQ ID NO:
- 1) in inhibiting angiogenesis, endothelial cell proliferation or endothelial tube formation in an in vitro or in vivo bioassay, or
- (b) an anti-angiogenic pharmaceutical composition that comprises the polypeptide of
- (a) and a pharmaceutically acceptable carrier,
- thereby inhibiting said undesired cell migration, cell invasion, cell proliferation or angiogenesis, or inducing apoptosis.
A method for treating a subject having a disease or condition associated with undesired cell migration, cell invasion, cell proliferation, or angiogenesis, which method comprises administering to the subject an effective amount of an anti-angiogenic pharmaceutical composition that comprises:
- (a) a polypeptide that is
- (i) a variant of native HK-D3 (SEQ ID NO:
- 1) designated HK-D3v, which has the amino acid sequence SEQ ID NO:
- 3, or
- (ii) a variant of native HK-D3 (SEQ ID NO:
- 1) that has an N-terminal addition and has the sequence SEQ ID NO:
- 2,
- wherein the polypeptide has at least 20% of the activity of native HK-D3 (SEQ ID NO:
- 1) in inhibiting angiogenesis, endothelial cell proliferation or endothelial tube formation in an in vitro or in vivo bioassay, and
- (b) a pharmaceutically acceptable carrier,
- thereby treating said subject.
Dependencies are inferred from the claim text.